Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-08-17 09:45 CEST (UTC+2h)

differents half life values [PK / PD]

posted by javier - Spain, 2017-03-16 17:49  - Posting: # 17158
Views: 885

Dear All

Reading about nivolumab, in the EPAR, there is a confusing information regarding the half life, im wondering if you dont mind to use your expertise to answer this question,
in the single dose pk study (with full pk sampling ) the half life was reported in 17 days, while in the multiple dose study (with sparse sampling) the half life was reported in 26 days, How could it be possible? How would you calculate the steady state in this situation?

I quote the exact word of the EPAR

"the mean terminal elimination half-life of nivolumab ranged between 17 and 27.5 days following single dose (study MDX1106-01) and Q2W administration (MDX1106-03) across the range of 0.1 to 10 mg/kg dose."

Thanks in advance for your time and dedication answering it

Best Regards


Edit: EPAR linked and category changed; see also this post #1. [Helmut]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,199 Posts in 3,683 Threads, 1,054 registered users;
32 users online (1 registered, 31 guests).

To call the statistician after the experiment is done
may be no more than asking him to perform a postmortem examination:
he may be able to say what the experiment died of.    R.A. Fisher

BEBAC Ing. Helmut Schütz